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Summary
An automated cartridge-based detection system (GeneXpert;
Cepheid) is being widely adopted in low throughput labora-
tories for monitoring BCR-ABL1 transcript in chronic
myelogenous leukaemia. This Australian study evaluated
the longitudinal performance speciﬁc characteristics of the
automated system. The automated cartridge-based system
was compared prospectively with the manual qRT-PCR-
based reference method at SA Pathology, Adelaide, over a
period of 2.5 years. A conversion factor determination was
followed by four re-validations. Peripheral blood samples
(n¼ 129) with international scale (IS) values within detectable
range were selected for assessment. The mean bias, pro-
portion of results within speciﬁed fold difference (2-, 3- and 5-
fold), the concordance rate of major molecular remission
(MMR) and concordance across a range of IS values on
paired samples were evaluated. The initial conversion factor
for the automated systemwas determined as 0.43. Except for
the second re-validation, where a negative bias of 1.9-fold
was detected, all other biases fell within desirable limits. A
cartridge-speciﬁc conversion factor and efﬁciency value was
introduced and the conversion factor was conﬁrmed to be
stable in subsequent re-validation cycles. Concordance with
the reference method/laboratory at >0.1–10 IS was 78.2%
and at 0.001 was 80%, compared to 86.8% in the >0.01–
0.1 IS range. The overall and MMR concordance were
85.7% and 94% respectively, for samples that fell with-
in5-fold of the reference laboratory value over the entire
period of study. Conversion factor and performance speciﬁc
characteristics for the automated system were longitudinally
stable in the clinically relevant range, following introduction by
the manufacturer of lot speciﬁc efﬁciency values.
Key words: Automated quantitation, BCR-ABL1, chronic myelogenous
leukemia, CML, monitoring, qRT-PCR.
Received 12 February, revised 9 May, accepted 21 May 2015
INTRODUCTION
The BCR-ABL1 fusion transcript characterises the myelo-
proliferative neoplasm chronic myelogenous leukaemia
(CML) and is the basis for diagnosis and monitoring of the
disease.1 Karyotyping, fluorescent in situ hybridisation (FISH)
and reverse transcriptase polymerase chain reaction (RT-PCR)
are all techniques that are employed to establish a diagnosis of
chronic myeloid leukaemia. In about 90–95% of subjects with
CML in chronic phase, where t(9;22) is the sole abnormality,
monitoring of minimal residual disease with quantitative RT-
PCR (qRT-PCR) is standard clinical practice for follow-up.1
Over the last few years, an automated cartridge-based detec-
tion system (GeneXpert; Cepheid, USA) has become available
with comparable limits of detection, sensitivity, specificity, and
a more rapid turnaround time with a favourable cost analysis.2
The automated cartridge-based assay (GeneXpert) performs
RNA extraction, cDNA production, nested real-time PCR and
signal detection in a single cartridge directly from a whole
blood sample. Markedly raised white cell count, delay in testing
(>48 h sample processing time) and change in the lot numbers
of the cartridges have been recognised as the cause of error for
the cartridge-based automated system.3
A longitudinal evaluation of performance specific charac-
teristics of the automated cartridge based system was
undertaken at Hunter Area Pathology Service/Pathology
North-Hunter, Newcastle, NSW, Australia (HAPS), which
was designated the primary laboratory, against a manual tech-
nique performed at SA Pathology (Adelaide, South Australia),
which was the reference laboratory. The SA Pathology labora-
tory serves as and is recognised worldwide as a reference centre
for BCR-ABL1 testing in CML.4,5 This study was specifically
undertaken to evaluate independently the validity and longi-
tudinal stability of the conversion factor as well as other
performance characteristics of the automated cartridge-based
system. The specific characteristics evaluated included the
mean bias, proportion of results within specified fold difference
(2-, 3- and 5-fold), the concordance rate of major molecular
remission (MMR) as well as concordance across a range of IS
(international scale) values on paired samples using the auto-
mated cartridge system compared with the reference manual
qRT-PCR.
DESIGN AND METHODS
Laboratories, subjects and validations
The automated cartridge-based qRT-PCR on GeneXpert was performed at
HAPS and validation by the reference manual qRT-PCR was undertaken at
SA Pathology. The study cohort was chosen from a total of 275 peripheral blood
samples from subjects with CML who were tested consecutively between
January 2011 and June 2013 for either routine diagnosis or monitoring. Out
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of these, 129 paired samples were chosen as they had both whole blood and
Trizol aliquots available. All samples were processed within 24 h of receipt at
HAPS laboratory and Trizol was used to stabilise the RNA prior to being sent to
the reference laboratory. Four samples were excluded (inadequate), so 125
paired samples were tested across both laboratories. The fold-change and
concordance was evaluated on 109 samples, as samples where the transcript
was either undetectable or >10% IS were excluded for this comparison.
The conversion factor determination was completed in May 2011 and
subsequent revalidation cycles were planned prospectively at approximately
6 monthly intervals or with lot number change for automated cartridges,
whichever occurred earlier (between July 2011 and June 2013).
Testing BCR-ABL1 by GeneXpert automated cartridge technique and
manual reference qRT-PCR method
GeneXpert cartridges and reagent solutions were purchased from the manu-
facturer (Cepheid, USA). The assays were run, according to the manufacturer’s
protocol, on the GeneXpert IV DX system for the entire period of the study. The
Trizol sample was analysed by manual duplicate qRT-PCR analysis at the
reference laboratory as previously reported.5
Establishment, stability of conversion factor and concordance analysis
The difference between the manual reference method and the automated system
was plotted against the mean of the methods for bias plot (Bland and Altman).
The 95% limits of agreement was estimated by mean difference 1.96 standard
deviations (SDs) of difference, which provided an interval within which 95% of
differences between measurements were expected to lie. The antilog of esti-
mated mean bias between methods was designated as conversion factor.6 Only
raw values obtained on the automated method were used for measurement of
conversion factor in all validation cycles. The manufacturer (Cepheid) provided
a lot specific conversion factor as well as specific efficiency (E DCt) values after
the second revalidation cycle for the automated cartridge. The manufacturer’s
conversion factor was compared to the conversion factor obtained by the inter-
laboratory revalidation cycles. The values for reporting MMR 0.1 IS) were
defined as per the International Randomized Study of Interferon and STI571
(IRIS) trial and the subsequent international standardisation efforts.6–9
Statistics and ethics
The data were analysed and graphed using XLSTAT (Addinsoft, USA) and
Analyse-it software (UK), where appropriate. The study was conducted as per
the ethical requirements for a quality assurance project at both sites.
RESULTS
Patient bias conversion factor determination and ﬁrst re-
validation
The initial conversion factor obtained after comparison with the
reference method was determined to be 0.43 (calculated as
antilog of bias). It was observed that 86% of the samples fell
within 5-fold of the reference laboratory value when this
conversion factor was employed. The first re-validation that
followed demonstrated stability of the conversion factor at 0.43
(Table 1). The log bias ranged from 0.23 to 0.08 in the first
revalidation and results were obtained on a cartridge with the
same lot number as the initial base line conversion factor
determination (Fig. 1A).
Subsequent revalidations
A total of five cartridge lot number changes occurred in the
period of the study. Two cartridge lot number changes occurred
between the second and third revalidations in short time frames
of within 4 weeks where no separate revalidation could be
undertaken. This resulted in a total of four revalidations for the
entire study period.
The log bias for revalidation cycles 2 to 4 ranged from 1.9
to 1.0 (Fig. 1B–E). A significant negative deviation from the
reference method was seen in cycle 2 where mean bias was
1.9 (Fig. 1C). A change to instrument software utilising lot
specific conversion factor and ‘efficiency values’ for cartridges
was introduced after the second validation; this value being
unavailable to the instrument users prior to this time point (July
2012). The bias was recalculated with raw values in the
subsequent cycles 3 and 4. It was also observed that the
manufacturer’s conversion factor that was subsequently pro-
vided matched the conversion factor obtained by our compari-
son with the reference laboratory.
Proportion within 2-, 3- and 5-fold difference from
reference method
The proportion of samples falling within 2-, 3- and 5-fold of the
reference laboratory values prior to and after the conversion to
the IS for each of the revalidation cycles are shown in the Table
1. Across the four revalidation cycles, 94% of the results fell
within 5-fold of the reference lab values (range 92–97%).
There were only five samples across the four revalidation
cycles that were greater than 5-fold difference from the refer-
ence laboratory values.
Concordance for MMR, high and low IS values
An overall concordance of 85.7% (54/63) for MMR was
observed across the four revalidation cycles. The overall con-
cordance for any IS value obtained in HAPS, when compared to
the reference laboratory, was 76.1% (83/109). Table 2 shows
specific grouping of results according to the level of inter-
national standard values. A concordance rate of 80% was
achieved in IS values 0.001, concordance of 78.2% was
achieved in values between >0.1 and 10% IS whereas
86.8% concordance was achieved in values >0.01 to 0.1
IS. A concordance rate of 75.5% (74/98) and 85.7% (54/63) was
observed for all values >1 and 0.1 IS respectively, the two
clinically important decision points (data not shown in table).
Table 1 Conversion factor for each cycle and comparison of values pre and post-conversion as 2-, 3- and 5-fold difference from reference laboratory
Testing cycle/parameter
Calculated conversion
factor (manufacturer’s values)
2-fold
raw (%)
2-fold
post-conversion (%)
3-fold
raw (%)
3-fold
post-conversion (%)
5-fold
raw (%)
5-fold
post-conversion (%)
Baseline conversion factor
determination (n¼ 21)
0.43 (NA) 7 (33) 14 (67) 11 (52) 17 (81) 81 (86) 18 (86)
1st revalidation cycle (n¼ 25) 0.43 (NA) 13 (52) 15 (60) 17 (68) 20 (80) 21 (84) 23 (92)
2nd revalidation cycle (n¼ 22) 0.47 (NA) 15 (68) 13 (59) 18 (82) 19 (86) 22 (100) 21 (95)
3rd revalidation cycle (n¼ 12) 0.47 (0.47) 3 (25) 11 (92) 8 (67) 11 (92) 12 (100) 11 (92)
4threvalidation cycle (n¼ 29) 0.47 (0.47) 6 (21) 24 (83) 15 (52) 26 (90) 26 (90) 28 (97)
The manufacturer also provided a lot speciﬁc efﬁciency value for cycles 3 and 4 which was incorporated into the instrument software after July 2012. The conversion
factor determined by the manufacturer is provided in brackets for cycles 3 and 4.
The % is calculation of the percentage of the reference laboratory’s results.
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DISCUSSION
The IRIS trial demonstrated that the international scale for
reporting of qRT-PCR results for BCR-ABL1 transcripts is key
to the optimal management of CML. The baseline value, which
represents 100% on IS and the 3-log reduction from standar-
dised baseline, which is fixed at 0.1 IS (as criteria for MMR) are
considered the two critical values.7 Failure to achieve MMR
and more recently10% at 3 months post-initiation of tyrosine
kinase inhibitor (TKI) therapy represents a warning res-
ponse.10,11 We report the results on a large independent longi-
tudinal evaluation of performance specific characteristics
which includes validity and longitudinal stability of conversion
factor, proportion of results within 2-, 3- or 5-fold difference,
MMR concordance and within a range of IS values of the
automated cartridge system for quantitation of BCR-ABL1
across two laboratories in Australia.
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Fig. 1 Bias plots for initial baseline conversion factor determination (A) and four subsequent revalidation cycles (B–E).
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Several previously published studies provide variable infor-
mation regarding some features of the automated cartridge-
based system but none have comprehensively evaluated the
specific performance characteristics of the automated car-
tridge-based system. During the process of the initial standard-
isation of the automated cartridge-based technique, Winn-Deen
et al. showed good concordance in spite of a high coefficient of
variation (CV) in samples with qRT-PCR results <0.01 IS.3 In
a study by Jobbagy et al., the cartridge based system was able to
detect BCR-ABL1 reliably and correlated well with the refer-
ence assay.12 They determined that the CVs were around 40%
for IS values in range of 0.1 and this was comparable to the
qRT-PCR technique employed in their experiments. Cayuela
et al. assessed inter-laboratory variability between the two
methods in which they observed a 90% MMR concordance
with the concordance dropping to between 60–70% at deeper
levels of molecular response.2 In the recent study by O’Dwyer
et al., the performance of the GeneXpert system in a cohort of
subjects on nilotinib showed a progressive decline in corre-
lation between the methods, as the log IS level declined.13,14 An
international collaborative effort from laboratories using the
manual reference method described three groups of laboratories
in comparison with the Adelaide reference laboratory with 91%
(group 1), 74% (group 2) and 60% (group 3) MMR concor-
dance rates.6 In this study, it was also observed that 95% of the
results fell within 5-fold of the reference laboratory’s value for
the group 1 laboratories.
The initial conversion factor established for the HAPS
facility on the cartridge-based system was 0.43 and the results
for first validation cycle followed the recommendations of
previous standardisation efforts.6 The mean bias was within
acceptable limits except for the second revalidation cycle. A
significant negative deviation of the mean bias from the
reference method (1.9) was noted during this second revali-
dation cycle resulting in lower than expected results on the
automated system. Discussion with the manufacturer con-
firmed that there had been a change in lot numbers of the
cartridges just prior to this revalidation. The manufacturer, at
that point in time, had also independently observed a drift in
their results leading to introduction of a lot specific conversion
and efficiency factor to reduce lot-to-lot variability of car-
tridges (personal communication). Cartridges that included
software-incorporating lot-specific ‘efficiency values’ were
subsequently introduced and revalidation in cycle 3 as well
as cycle 4, returned results of mean bias within desirable range.
In this study, revalidations were planned to coincide with lot
number changes for the automated cartridges or every 6months,
whichever occurred earlier. This enabled the detection of the
negative bias in the second revalidation cycle.
It was observed that across the four revalidation cycles
92–97% of values were within 5-fold of reference laboratory
value after conversion, which is comparable to the results of
group 1 (best performing) laboratories. The automated car-
tridge system showed an overall MMR (0.1 IS) concordance
of 85.7%, which was close to group 1 (best performing)
laboratories in the multicentre international study.6 An
86.8% concordance was observed for values >0.01 to
0.1 IS which was also close to best performing (group 1).
An 80% concordance was achieved in values between >0.001
and  0.01 IS performing between group 1 and group 2
laboratories from the international standardisation effort.6
Between values of >0.1 and 10 IS, the concordance dropped
to 78.2% with a performance that is closer to group 2 labora-
tories in the international study.6 The discordance between
laboratories seen in up to 22% (the range being 14–22% as
shown in Table 2), particularly seen at higher IS values, needs
to be considered when evaluating samples for BCR-ABL1
transcript levels at 3 months or levels that determine time to
achieve t1/2 from baseline, both of which are now considered
important for long-term prognosis based on emerging
data.10,11,15,16 This has direct clinical relevance where con-
secutive samples in a given patient are measured in different
laboratories or using different techniques at ‘clinically deci-
sive’ transcript levels. For example, achievement of a 1% and
subsequent 0.1% is important and measuring the levels by two
methods may give results with several-fold difference. In the
international study comparing 38 laboratories that used a
variation of manual RT-PCR technique, the MMR concordance
ranged from 60% to 91%.6 In our study a 75.5% and 85.7%
concordance rate was observed at 1% and 0.1% IS and this
reflects the need for serial monitoring in any given analytical
system.
Our study did not specifically evaluate the clinical risk
scores, treatment regimens and specific clinical outcomes with
the PCR results. We also did not evaluate values 0.001 (close
to MR4.5 value) given the very few samples in this range
(n¼ 6) from the initial cohort. As the values approach 0.0032 IS
or less, the limits of detection by any current methodology are
potentially reached. At very low levels of minimal residual
disease (MRD), stochastic effects become more important and
imprecision increases in quantitative assays.17 Replicate assays
may improve sensitivity but this is difficult to achieve in the
diagnostic setting where the starting material is usually limited
and costs prohibitive. Moreover, the actual rate of degradation
may vary between whole blood and Trizol samples, thus
introducing a pre-analytical variable that is difficult to control
for and may well influence the discrepancies noted at this low
level of detection.
Apart from inbuilt housekeeping genes and manufacturer’s
controls, independent control samples are not commercially
available for quality assurance of the automated cartridge
system. Most external quality assurance programs use Trizol
samples, not whole blood, and have been developed to be
suitable for manual qRT-PCR systems.18–20 The manufacturer
Table 2 Concordance at various IS values and for MMR
Samples as per IS values
HAPS GeneXpert assay
automated cartridge based method
SA Pathology manual
reference qRT-PCR method
Concordance between the
two methods n (%)*
Values >0.1 and 10 IS 39 46 36 (78.2)
Values >0.01 and 0.1 IS 53 53 46 (86.8)
Values >0.001 and 0.01 IS 17 10 8 (80)
* The % is calculated as the percentage of the reference laboratory’s results.
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of the automated system now reports standardisation of every
lot of cartridge with a World Health Organization (WHO)
BCR-ABL1 standard and provides an IS conversion factor
as well as efficiency factor in order to eliminate the source
of variation as observed in the second validation cycle in this
study. This has ensured the overall stability of the conversion
factor. The recent development of synthetic armoured RNA
quant (ARQ) analytical reference panels calibrated to WHO
primary standards, for generating four level curves, is also
likely to achieve greater standardisation.20 At this stage, we
have continued to perform validations against the reference
laboratory at 6 monthly intervals or at every change in lot
number to continue monitoring the performance of the auto-
mated system. This also provides an opportunity to observe
concordance at high or low IS values which are emerging as
critical values for management of CML given that greater
numbers of low throughput laboratories, particularly in the
Asia-Pacific region, are now adopting the automated cartridge-
based system.21 A collated international experience in the form
of a prospective study would be useful to determine how
intensively such systems need to be monitored and revalidated.
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